Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Total Current Liabilities (2016 - 2025)

Traws Pharma (TRAW) has disclosed Total Current Liabilities for 14 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 3.36% year-over-year to $11.1 million; the TTM value through Dec 2025 reached $11.1 million, down 3.36%, while the annual FY2025 figure was $11.1 million, 3.36% down from the prior year.
  • Total Current Liabilities hit $11.1 million in Q4 2025 for Traws Pharma, up from $7.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $11.5 million in Q4 2024 and bottomed at $5.9 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $8.4 million, with a median of $8.2 million recorded in 2022.
  • Year-over-year, Total Current Liabilities tumbled 38.98% in 2021 and then skyrocketed 55.08% in 2023.
  • Traws Pharma's Total Current Liabilities stood at $6.1 million in 2021, then soared by 31.58% to $8.0 million in 2022, then rose by 14.59% to $9.2 million in 2023, then increased by 25.09% to $11.5 million in 2024, then fell by 3.36% to $11.1 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $11.1 million, $7.9 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.